-
2025-521147-21-00
4
2025-10-08
Lung Cancer
-
2024-519188-17-00
1
2025-10-07
Relapsed/refractory malignancy with documented diagnosis of human epid
-
2024-518358-17-00
4
2025-10-06
Squamous cell carcinoma of the esophagus
-
2024-515249-41-00
10
2025-10-01
Cardiorespiratory arrest at birth in full-term newborns
-
2024-517671-21-00
5
2025-09-30
Coronavirus Disease 2019 (COVID-19)
-
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
-
2024-520386-31-00
5
2025-09-22
Locally Advanced Head & Neck Squamous Cell Carcinoma
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2025-520672-26-00
9
2025-09-16
Gastrointestinal Neoplasms
-
2024-511663-28-00
6
2025-09-11
Asymptomatic Child-Pugh A5 to B8 cirrhosis
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2024-513955-34-00
9
2025-09-09
Proven pathogenic or probably pathogenic TBR1 variant
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-514954-63-00
9
2025-08-20
RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2022-502983-19-00
4
2025-07-31
High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2023-510449-51-00
5
2025-07-31
Adult ICU patients with septic shock
-
2024-512583-57-00
5
2025-07-30
HER2-positive locally advanced or metastatic gastric or gastroesophage
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-516418-39-00
5
2025-07-09
Multiple Myeloma
-
2024-516780-93-00
5
2025-07-09
Sustained immunosuppression
-
2024-518829-15-00
9
2025-07-02
previously untreated chronic lymphocytic leukemia (CLL)